Adaptimmune Therapeutics (ADAP) Stock Analysis: AI Score & Alternative Data
Alt-data signals are cooling for Adaptimmune Therapeutics
Is Adaptimmune Therapeutics a buy right now? The alternative data says hold. This ADAP stock analysis is built on the 25+ alternative data signals AltIndex tracks on Adaptimmune Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 48/100: a Hold. The stock trades at $0.05 with a $15M market cap.
The soft spots over the past 90 days: revenue down 92.3% YoY to $10M. The rest of the signal set is holding steady, which keeps ADAP at a hold rather than a sell.
ADAP’s broader alt-data profile also covers web traffic (7K monthly visits), and sentiment (95/100). Every signal links to its own page with full history, the ADAP technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on ADAP is just below.
Adaptimmune Therapeutics AI Stock Analysis
Adaptimmune Therapeutics is a biotechnology company specializing in the development of T-cell therapy approaches to treat cancer. The company uses proprietary technologies to engineer T-cells to target and kill cancer cells. Adaptimmune's focus remains on developing its pipeline of SPEAR T-cells aimed at treating a variety of cancers.
Analysis generated July 1, 2026.
Recent Adaptimmune Therapeutics Stock Alerts
|
Adaptimmune Therapeutics | October 27 Price is up by 6.2% in the last 24h. |
|
Adaptimmune Therapeutics | October 24 Price is down by -10.7% in the last 24h. |
|
Adaptimmune Therapeutics | October 23 Price is down by -7.5% in the last 24h. |
|
Adaptimmune Therapeutics | October 22 Price is up by 9.1% in the last 24h. |
Adaptimmune Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 7K | 0% | |
| Sentiment | 95 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | 0% | |
| Stocktwits Mentions | 1K | 0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 11K | 0% | |
| 4chan Mentions | 0 | N/A |
About Adaptimmune Therapeutics (ADAP)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to solid tumor patients in the United States and the United Kingdom. The company is headquartered in Abingdon, the United Kingdom.
| Price | $0.05 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $15M |
| Year Range | $0 – $0 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Adaptimmune Therapeutics News
View more →
Tumor Microenvironment Market to Reach Over $2.7 Billion by 2030 - Rising Demand for Personalized Oncology Therapies and Next-Gen Immunotherapies Driving the IndustryApril 2 - GlobeNewswire |
|
$1.59 Billion PD-1 Resistant Head and Neck Cancer Market Analysis Report 2026: Size, Growth, and Segmentation Insights to 2030March 30 - GlobeNewswire |
|
Advanced Melanoma Markets and Companies 2026-2030: Cumulative Revenue to Grow by $1.87 BillionMarch 30 - GlobeNewswire |
Adaptimmune Therapeutics Earnings & Financial Performance
View all earnings →Adaptimmune Therapeutics Insider Trading Activity
View all →| Wood Gavin filed to sell 0 shares at $0.0. Sep 2 '25 |
| Bertrand William C JR filed to sell 986,352 shares at $0.0. Aug 28 '25 |
| Behbahani Ali filed to sell 0 shares at $0.0. Aug 18 '25 |
| Behbahani Ali filed to sell 14,671,794 shares at $0.0. Aug 15 '25 |
| EcoR1 Capital, LLC filed to sell 100,371,882 shares at $0.0. Jul 30 '25 |
Adaptimmune Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Adaptimmune Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Zivo BioscienceZIVO |
$4.75 9.5% | $15M | 46 |
 |
Cocrystal PharmaCOCP |
$1.01 2.9% | $14M | 48 |
 |
Cyclerion TherapeuticsCYCN |
$3.82 2.8% | $15M | 52 |
 |
Vyome HoldingsHIND |
$2.18 2.2% | $15M | 52 |
 |
Jasper TherapeuticsJSPR |
$0.60 3.0% | $13M | 50 |
Explore Adaptimmune Therapeutics Data
Frequently Asked Questions: Adaptimmune Therapeutics (ADAP)
Adaptimmune Therapeutics has an AltIndex AI Score of 48/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
48/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Adaptimmune Therapeutics (ADAP) stock is $0.05 with a market cap of $15M.
As of today, Adaptimmune Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Adaptimmune Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Adaptimmune Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The ADAP stock price chart above shows Adaptimmune Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Adaptimmune Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Adaptimmune Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
